Livzon Pharmaceutical Group Inc. Announces Results of Major Public Tender Offer for Imexpharm Corporation

Livzon Pharmaceutical Group Inc. (“Livzon” or “the Company”) has provided a comprehensive update concerning its proposed acquisition of equity interests in Imexpharm Corporation (“IMP”), a listed pharmaceutical company in Vietnam. This transaction, which has been progressing since May 2025, represents a significant strategic move for Livzon and is likely to be of considerable interest to shareholders and investors.

Key Points of the Transaction

• Board Approvals: The acquisition proposal and tender offer for IMP shares were approved at the 25th and 31st meetings of Livzon’s 11th Board of Directors, held on 22 May 2025 and 30 December 2025, respectively. The Board resolved to allow LIAN SGP HOLDING PTE. LTD. (“LIAN SGP”), a Livzon subsidiary, to proceed with a voluntary public tender offer for all IMP shares, in accordance with Vietnamese regulations.
• Offer Size and Price: The upper limit for the tender offer was set at 120,059,970 shares, representing approximately 77.94% of IMP’s registered capital and 77.96% of its voting shares. The offer price was VND57,400 per share (approximately RMB15.37 at the time of Board approval).
• Tender Offer Results: At the close of the tender period, LIAN SGP had acquired 104,545,781 shares of IMP, amounting to 67.87% of registered capital and 67.88% of voting shares. The total consideration for the acquisition is VND6,000,927,829,400 (approximately RMB1.562 billion).
• Next Steps: LIAN SGP will proceed with payment and share delivery procedures. The Company highlights that the transaction remains subject to several uncertainties, including market changes, completion of subsequent steps, and the approval procedures of all relevant parties.

Important Information for Shareholders

• Potential Impact on Share Price: This is a major cross-border acquisition that significantly expands Livzon’s presence in the Southeast Asian pharmaceutical market. The scale of the transaction—acquiring a controlling interest in a leading Vietnamese pharmaceutical company—could have a material impact on Livzon’s financial results, strategic positioning, and long-term growth prospects. Such developments are typically considered price sensitive and may affect the Company’s share value.
• Regulatory Compliance and Risks: The Company will continue to comply with all relevant laws and regulations, including those of China, Vietnam, and the Hong Kong and Shenzhen Stock Exchanges. Livzon cautions that the transaction is still subject to uncertainties, including regulatory approvals and market factors. Investors are urged to exercise caution.
• Disclosure Commitment: Livzon has committed to strict compliance with disclosure and review obligations, ensuring shareholders are kept informed of all significant developments.

Corporate Governance

As of 29 April 2026, the Board comprises Mr. Zhu Baoguo (Chairman), Mr. Tang Yanggang (Vice Chairman), other Non-Executive Directors, one Employee Representative Director, and four Independent Non-Executive Directors. The Company Secretary is Ms. Liu Ning, and the Company is headquartered in Zhuhai, China.

Conclusion

Livzon’s acquisition of a majority stake in Imexpharm Corporation represents a transformative step in the Company’s international strategy, potentially enhancing its market footprint and shareholder value. However, shareholders should be aware of the ongoing risks and uncertainties associated with cross-border acquisitions.

Disclaimer: This article is for information purposes only and does not constitute investment advice. Investors are strongly advised to conduct their own due diligence and consult professional advisors before making any investment decisions. Livzon Pharmaceutical Group Inc. and its Board accept no responsibility for any losses arising from reliance on this article.

View LIVZON PHARMA Historical chart here